Tyrogenex to Present at the Landmark Venture Forum at the Boca Raton Resort and Club - Boca Raton, FL

Feb 19, 2016, 08:18 ET from Tyrogenex

NEEDHAM, Mass., and PALM BEACH GARDENS, Fla., Feb 19, 2016 /PRNewswire/ -- Tyrogenex, a privately held biopharmaceutical company, announces its participation as a Presenting Company at the Landmark Venture Forum at the Boca Raton Resort and ClubBoca Raton, FL

Michael D. Webb, Tyrogenex CEO, will present on February 25, 2016.

Tyrogenex is developing X-82, an orally-administered dual vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) inhibitor, for wet age-related macular degeneration (wet AMD) and solid tumors.

For wet AMD, one of the leading causes of blindness for people over the age of 50 that affects more than 1.5 million Americans, the company is enrolling patients in the APEX phase 2 trial for the treatment of wet AMD.

About Landmark Angels

Landmark Angels invests in opportunities ranging from $100K to $2M with the ability to syndicate with other angel and venture capital groups.  Companies are selected from industry contacts and conferences, leading education institutions, and direct applications.  Landmark Angels provides entrepreneurs with the capital, invaluable advice, and key industry contacts to succeed in an ever evolving environment where new technologies are developed at a demanding pace.

About Tyrogenex
Tyrogenex is a biopharmaceutical company focused on improving the lives of patients with wet AMD and solid tumors by discovering medicines to help provide additional treatment options. Tyrogenex's lead compound is X-82. For more information, visit www.tyrogenex.com

About X-82
Tyrogenex's lead compound is X-82.  X-82 inhibits both VEGF and PDGFR. Tyrogenex believes X-82 targets the basic mechanisms of neovascular eye diseases, including angiogenesis, fibrosis and inflammation.  X-82 is currently being evaluated for wet AMD and solid tumors.

About Wet AMD
AMD is the leading cause of blindness for people over the age of 50 in the United States and Europe. There are two forms of the disease, namely "dry" and "wet" AMD. Wet AMD is characterized by the growth of new blood vessels into the central region of the retina. These new and abnormal blood vessels cause severe central vision loss due to retinal damage caused by leakage of the blood vessels and subsequent scar formation.

Forward-Looking Statements
This press release contains forward-looking statements that are based on company management's current beliefs and expectations and are subject to currently unknown information, risks and circumstances and actual results may vary from what is being currently projected.

Corporate Contact:
Teri Swift
Tyrogenex Corporate Communications
(561) 406-9705
teri@tyrogenex.com

Logo - http://photos.prnewswire.com/prnh/20151113/287174LOGO

SOURCE Tyrogenex



RELATED LINKS

http://www.tyrogenex.com